•  
  •  
  •  
  •  

2026-08-12 00:50:35

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  NatcoPharma

Research

  • Natco Pharma - Natco and Teva launch Revlimid in the US - ICICI Securities

Stock Report

  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • NATCO receives Tentative Approval for Olaparib Tablets from the U.S. FDA
  • NATCO Pharma Ltd completes acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Ltd
  • NATCO Pharma Ltd gets approval from its Board of Directors for increasing its stake in Adcock Ingram Holdings Proprietary Ltd to 49%
  • NATCO and Lupin receive approval from U.S. FDA for Eribulin Mesylate Injection
  • NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290
  • NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst&®) in the U.S. market
  • Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India
  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • NATCO Pharma Ltd receives 7 Observations from USFDA for API unit at Manali, Chennai
  • Adcock ingram completes delisting from JSE; NATCO Pharma acquires 35.75% stake
  • NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)
  • NATCO Pharma Limited - Legal update regarding Risdiplam
  • Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal
  • NATCO Pharma Ltd updates on acquisition of Adcock Ingram
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur
  • USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
  • NATCO Pharma Ltd - Legal Update regarding Risdiplam
  • Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic
  • NATCO Pharma Canada Inc. announces US$ 8 million investment in eGenesis, Inc.
  • Natco Pharma Ltd announces submission of Abbreviated New Drug Application
  • NATCO Pharma Ltd updates on complaint by Fresenius
  • NATCO Pharma Ltd receives warning letter from USFDA for facility in Kothur, Telangana

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025